Local Manufacturing Partnership launched in Iran
Tehran, Iran; 29 October 2015: The Ministry of Health and Medical Education in Iran has recently welcomed the three-way partnership agreement between itself, Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), and Behestan Group for the manufacturing of urology and transplantation pharmaceutical products. The existing manufacturing plant, owned by Behestan Tolid, will receive a technology transfer from Astellas enabling it to produce Astellas pharmaceuticals for the Iranian market.
A ceremony event celebrating the partnership took place at the Parsian Azadi Hotel in Tehran with high ranking government officials, representatives of both Astellas and Behestan Group, and several distinguished Health Care professionals, representatives of medical societies, and members of the press in attendance.
Behestan Tolid’s manufacturing facility will make two key urological products Vesicare and Omnic®, and one transplantation product, Prograf®. Currently the site already handles the packaging of Omnic® and Prograf®. With the technology transfer from Astellas, Behestan Tolid will manufacture all three of these pharmaceuticals, which amounts to approximately 450- 500 million tabs and 150 million caps per year. The pharmaceuticals will be made available to all medical institutions in the country.
Commenting on the partnership, Dr. Mahyar Balouchestani, CEO, Behestan Tolid stated: “Our manufacturing site already produces products from international pharmaceutical companies, and this technology transfer from Astellas will add three more world class products to our portfolio. Distributing these pharmaceutical products to the Iranian market will ensure that our community receives the best products manufactured at a first class facility.”
Omnic is used for benign prostatic hyperplasia and Vesicare is prescribed for to the treatment of Over Active Bladder (OAB), conditions that significantly affect patients’ quality of life. Prograf® belongs to a group of medicines called immunosuppressants. The medication supresses the immune system’s response following an organ transplant to enable the body’s acceptance of the newly transplanted organ.
Mr. Markus Weber, General Manager, Astellas MENA/SSA, concluded: “Supporting the Ministry of Health’s progressive plans in Iran is a significant part of our strategic direction at Astellas MENA/SSA. Astellas is facilitating a technology transfer with our partner Behestan Tolid for the manufacturing of our urological and transplantation products. There is a need in the market for relevant medications that will enhance the quality of life for patients in Iran and we look forward to developing this partnership to better serve this community.”
The manufacturing facility operates according to the Good Manufacturing Practice (GMP) international certification.
– ENDS –